Company intelligence / Profile preview

Pharvaris

Ownership: Public · PHVS
Development stage: Phase 3

Overview

Pharvaris has achieved target enrollment in RAPIDe-3, a pivotal Phase 3 study for on-demand treatment of HAE attacks. Enrollment is underway in CHAPTER-3, a pivotal Phase 3 study for prophylaxis of HAE attacks with topline data expected in 2H2026. The company has received orphan medicinal product designation for deucrictibant in Europe. Recent data shows deucrictibant's ability to maintain reduced attack rates in long-term prophylaxis and potential to rapidly treat HAE attacks, including upper-airway attacks.

Therapeutic areas: Immunology
Modalities: Small molecules (oral bradykinin B2 receptor antagonists)
Industry: Biotech

Drug pipeline

1 asset

deucrictibant

Financials

Market cap: $2.6B
Total revenue: $0
Enterprise value: $2.3B

Beyond the preview

Go deeper on Pharvaris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharvaris.

Explore the full profile